3 results about "Platelet receptor" patented technology

This invention relates to an antibody or antigen-binding fragment of phosphorylated VASP-Ser 239 protein and its applications. The antibody comprises specific light and heavy chain variable region complementarity-determining region (CDR) sequences or amino acid sequences having at least 80% sequence identity with them. The invention also provides isolated polynucleotides encoding the antibody, expression vectors, recombinant cells, and methods for preparing the antibody. The antibody and its derivatives of this invention can efficiently and specifically detect phosphorylated VASP-Ser 239 protein in human whole blood or platelet cells, and are suitable for monitoring the inhibitory effect of platelet ADP receptor (P2Y12) antagonists (such as clopidogrel) on platelet activation, clarifying clopidogrel resistance, and guiding rational clinical drug use. This invention solves the current shortage of antibody raw materials and kits for related detection projects on the market.

The present invention provides engineered platelets having a chimeric platelet receptor (CPR) with desired target specificity. Furthermore, the engineered platelets may contain cargo that can be released upon platelet activation. In addition, the platelets can be generated in vitro from megakaryocytes engineered to produce non-thrombotic platelets. [Solution] To provide an engineered megakaryocyte or precursor capable of reducing thrombogenic ability and / or producing platelets with reduced thrombogenic ability, comprising the disruption or deletion of at least one gene encoding a protein involved in the recognition of a primary stimulus for thrombosis, one gene encoding a protein involved in the recognition of a secondary mediator for thrombosis, and one gene encoding a protein involved in the release of a secondary mediator for thrombosis.

The application belongs to the technical fields of polypeptide and biological medicine, and particularly relates to a polypeptide SR14 and application thereof. The amino acid sequence of the polypeptide SR14 is SCEPCQTLAVRSYR. The polypeptide SR14 composed of the amino acids can be effectively combined with a platelet receptor, interfere with the aggregation of thrombin-activated platelets, and then achieve the effect of anti-thrombus. Meanwhile, the polypeptide SR14 has a low risk of bleeding, and can be used for the preparation of anti-thrombus drugs.